Prospective Evaluation of Quality of Life and Neurocognitive Effects in Patients With Multiple Brain Metastases Receiving Whole-Brain Radiotherapy With or Without Thalidomide on Radiation Therapy Oncology Group (RTOG) Trial 0118

International Journal of Radiation Oncology Biology Physics

Volumn 71, Issue 1, 2008, Pages 71-78

  Corn, Benjamin W ^c   Moughan, Jennifer ^a   Knisely, Jonathan P S ^d   Fox, Sherry W ^b   Chakravarti, Arnab ^e   Yung, W K Alfred ^f   Curran Jr , Walter J ^g   Robins, H Ian ^j   Brachman, David G ^h   Henderson, Randal H ⁱ   Mehta, Minesh P ^j   Movsas, Benjamin ^k  

^a RADIATION THERAPY ONCOLOGY GROUP   (United States)

^b Cullather Brain Tumor Quality of Life Center   (United States)

^c TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^d YALE UNIVERSITY   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h ST JOSEPH'S HOSPITAL AND MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF FLORIDA   (United States)

^j UNIVERSITY OF WISCONSIN MADISON   (United States)

^k HENRY FORD HOSPITAL   (United States)

more..

Author keywords

Brain metastases; Neurocognition; Quality of life; Thalidomide; Whole brain radiotherapy

Indexed keywords

DRUG DOSAGE; ONCOLOGY; RADIOTHERAPY;

BRAIN METASTASES; NEUROCOGNITION; THALIDOMIDE; WHOLE-BRAIN RADIOTHERAPY;

BRAIN;

THALIDOMIDE;

ADULT; AGED; ARTICLE; BEDTIME DOSAGE; BRAIN METASTASIS; BRAIN RADIATION; CANCER GROWTH; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; COGNITION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; HUMAN; MAJOR CLINICAL STUDY; MENTAL DETERIORATION; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COMPLIANCE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; COGNITION; COGNITION DISORDERS; CRANIAL IRRADIATION; EDUCATIONAL STATUS; HUMANS; MENTAL STATUS SCHEDULE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PROSPECTIVE STUDIES; QUALITY OF LIFE; SURVIVAL ANALYSIS; THALIDOMIDE;

EID: 41749084819     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.09.015     Document Type: Article

References (36)

1. Langer C.J., and Mehta M.P. Current management of brain metastases, with a focus on systemic options. J Clin Oncol 23 (2005) 6207-6219
2. Li J., Bentzen S.M., Renschler M., et al. Regression of brain metastases after whole brain radiation therapy correlates with survival and improved neurocognitive function with brain metastases. J Clin Oncol 25 (2007) 1260-1266
3. Nieder C., Leicht A., Motaref B., et al. Late radiation toxicity after whole brain radiotherapy. The influence of anti-epileptic drugs. Am J Clin Oncol 22 (1999) 573-579
4. Komaki R., Meyers C.A., Shin D.M., et al. Evaluation of cognitive function in patients with limited small cell lung cancer prior to and shortly following prophylactic cranial irradiation. Int J Radiat Oncol Biol Phys 33 (1995) 179-182
5. Chang E.L., Wefel J.S., Maor M.H., et al. A pilot study of neurocognitive function in patients with one to three new brain metastases initially treated with stereotactic radiosurgery alone. Neurosurgery 60 (2007) 277-283
6. Mehta M.P., Rodrigus P., Terhaard C.H., et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole brain radiation therapy in brain metastases. J Clin Oncol 21 (2003) 2529-2536
7. Moscetti L., Nelli F., Felici A., et al. Upfront chemotherapy and radiation treatment in newly diagnosed non-small cell lung cancer with brain metastases. Survey of Outcomes Research Network for Evaluation of Treatment Results in Oncology. Cancer 109 (2007) 274-281
8. Stea B., Suh J.H., Boyd A.P., et al. Whole brain radiotherapy with or without efaproxiral for the treatment of brain metastases. Determinants of response and its prognostic value for subsequent survival. Int J Radiat Oncol Biol Phys 64 (2006) 1023-1030
9. Fine H.A., Figg W.D., Jackle K., et al. Phase II trial of the anti-angiogenic agent Thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 18 (2000) 708-715
10. Knisely J.P.S., Berkey B., Chakravarti A., et al. A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases (RTOG 0118). Int J Radiat Oncol Biol Phys 71 (2008) 79-86
11. Moinpour C.M., Lyons B., Schmidt S.P., et al. Substituting proxy ratings for patients in cancer clinical trials. An analysis based on a Southwest Oncology Group Trial in patients with brain metastases. Qual Life Res 9 (2000) 219-231
12. Spitzer W.O., Dobson A.J., Hall J., et al. Measuring the quality of life of caner patients. A concise QL index for use by physicians. J Chron Dis 34 (1981) 585-597
13. Choucair A.K., Scott C., Urtasun R., et al. Quality of life and neuropsychological assessment for patients with malignant astrocytoma. RTOG 91-14. Int J Radiat Oncol Biol Phys 38 (1997) 9-20
14. Murray K.J., Scott C., Zachariah B., et al. Importance of the Mini-Mental Status Examination in the treatment of patients with brain metastases. A report from the Radiation Therapy Oncology protocol 91-04. Int J Radiat Oncol Biol Phys 48 (2000) 59-64
15. Gaspar L., Scott C., Rotman M., et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37 (1997) 745-751
16. Scott C.B. Is radiation induced skin toxicity of the breast associated with reduced quality of life? Report of RTOG 97-13. Qual Life Res 7 B (1999) 572
17. Tangalos E.G., Smith G.E., Ivnik R.J., et al. The mini-mental status examination in general medical practice. Clinical utility and acceptance. Mayo Clin Proc 71 (1996) 829-837
18. Kaplan E.L., and Meier P. Non-parametric estimation from incomplete observations. J Am Statist Assoc 53 (1958) 457-481
19. Kalbfleish J.D., and Prentice R.L. The statistical analysis of failure time data (1980), John Wiley & Sons, New York pp. 167-169
20. Weitzner M.A. Psychosocial and neuropsychiatric aspects of patients with primary brain tumors. Cancer Invest 17 (1999) 285-291
21. Regine W.F., Huhn J.L., Patchell R.A., et al. Risk of symptomatic brain tumor recurrence and neurologic deficit after radiosurgery alone in patients with newly diagnosed brain metastases. Results and implications. Int J Radiat Oncol Biol Phys 52 (2002) 333-338
22. Chow E., Davis L., Holden L., et al. Prospective assessment of patient related symptoms following whole brain radiotherapy for brain metastases. J Pain Symptom Manage 30 (2005) 18-23
23. Gralla R.J., and Thatcher N. Quality of life assessment in advanced lung cancer. Considerations for evaluation in patients receiving chemotherapy. Lung Cancer 46 (2004) S41-S47
24. McCarter H., Furlong W., Whitton A., et al. Health status measurements at diagnosis as predictors of survival among adults with brain tumors. J Clin Oncol 24 (2006) 3636-3643
25. Efficace F., Horneber M., Lejeune S., et al. Methodological quality of patient reported outcome research was low in complementary and alternative medicine in oncology. J Clin Epidemiol 59 (2006) 1257-1265
26. Sehlen S., Lenk M., Hollenhorst H., et al. Quality of life as a predictive mediator variable for survival in patients with intracerebral neoplasia during radiotherapy. Onkologie 26 (2003) 38-43
27. Regine W.F., Schmitt F.A., Scott C.B., et al. Feasibility of neurocognitive outcome evaluation in patients with brain metastases in a multi-institutional cooperative group setting. Results of RTOG BR-0018. Int J Radiat Oncol Biol Phys 58 (2004) 1346-1352
28. Inagaki M., Yoshikawa E., Matsuoka Y., et al. Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer 109 (2007) 146-156
29. Sohlbach K., Heinze S., Shiratori K., et al. Encephalopathy in a patient after long-term treatment with thalidomide. J Clin Oncol 24 (2006) 4942-4944
30. DeAngelis L.M., Delattre J.Y., and Posner J.B. Radiation induced dementia in patients cured of brain metastases. Neurology 39 (1989) 789-796
31. Archibald Y.M., Lunn D., Ruttan L.A., et al. Cognitive functioning in long-term survivors of high grade glioma. J Neurosurg 80 (1994) 247-253
32. Brown P., Jensen A.W., Felten S.J., et al. Detrimental effects of tumor progression on cognitive function of patients with high grade glioma. J Clin Oncol 24 (2006) 5427-5433
33. Nys G.M., Van Zandvoort M.J., de Kort P.L., et al. Restrictions of the Mini-Mental Status Examination in acute stroke. Arch Clin Neuropsychol 20 (2005) 623-629
34. Meyers C.A., Smith J.A., Bezjak A., et al. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and Motexafin Gadolinium. Results of a randomized Phase II trial. J Clin Oncol 22 (2004) 157-165
35. Maire J.P., Coudin B., Guerin J., et al. Neuropsychologic impairment in adults with brain tumors. Am J Clin Oncol 10 (1987) 156-162
36. Shaw E.G., Rosdhal R., D'Agostino R.B., et al. Phase II study of donepezil in irradiated brain tumor patients. Effect on cognitive function, mood and quality of life. J Clin Oncol 24 (2006) 1415-1420